Baloxavir marboxil,
does it really help with Prevention of household influenza transmission after a single dose taken by the infected person?
research showsA single dose of baloxavir taken by an infected person reduces laboratory-confirmed influenza infection in household contacts, but it has not demonstrated a significant reduction in transmission that causes symptomatic illness, so the grade is C. In the phase 3b CENTERSTONE randomized trial, laboratory-confirmed transmission through day 5 fell from an adjusted 13.4% to 9.5%, while symptomatic transmission was 7.6% versus 5.8% and was not significantly different. The positive evidence is concentrated in one Roche-led trial with a virologic primary endpoint. A reduction in virus detection therefore cannot be expanded into proof that family members avoid illness, limiting the score to 52.
ads claimPromotion can translate lower viral load or fewer polymerase-chain-reaction-positive transmissions into a claim that family members will not catch influenza or become ill. The demonstrated scope is narrower: early single-dose treatment of the index patient reduced laboratory-confirmed infection in contacts, while prevention of symptomatic illness remains unconfirmed.
Useful facts when choosing a product
- Baloxavir marboxil is a prescription inhibitor of the influenza cap-dependent endonuclease, and Xofluza is its best-known brand. A weight- and age-appropriate dose is taken once, as early as possible after symptom onset, according to the approved label.
- Milk, calcium-fortified drinks, antacids, and products containing polyvalent cations such as iron, magnesium, zinc, or selenium can impair absorption and should not be taken together. The product label and prescription determine exact timing and dose.
- Reported adverse events include diarrhea, bronchitis, nausea, and headache and are usually mild, although hypersensitivity can occur. Pregnancy, lactation, severe or complicated disease, and influenza requiring hospitalization require separate evidence and treatment decisions.
- Viruses with reduced susceptibility, particularly PA I38 substitutions, can emerge after treatment, and resistant virus was observed in treated index patients in CENTERSTONE. This safety and public-health concern is recorded separately from efficacy against laboratory-confirmed transmission.
What the research actually shows
CENTERSTONE randomized 1,457 influenza index patients across multiple countries and the 2019-to-2024 seasons to single-dose baloxavir or placebo and followed 2,681 household contacts. Adjusted laboratory-confirmed transmission through day 5 was 9.5% versus 13.4%, with an adjusted odds ratio of 0.68, whereas symptomatic transmission was 5.8% versus 7.6%, with an odds ratio of 0.75 that was not significant. Drug-resistant virus emerged during follow-up in 7.2% of treated index patients. CAPSTONE-1 was a separate personal-treatment trial in which one dose shortened symptom-alleviation time by about 26.5 hours versus placebo; it did not test household transmission prevention.
Why this is classified as C (52)
In the large CENTERSTONE randomized trial, laboratory-confirmed household transmission declined significantly from 13.4% to 9.5%. Symptomatic transmission, however, was not significantly different at 7.6% versus 5.8%, and positive evidence is concentrated in one Roche-led trial with a virologic outcome. Because a surrogate cannot be expanded into prevention of clinical illness in family members, rules ① and the principle of sponsor concentration support C with 52 points.
Counterpoint. Reduced laboratory-confirmed infection may matter for infection control, but it does not replace vaccination, isolation, ventilation, or hand hygiene. Whether to prescribe primarily for household protection depends on timing, patient risk, and current indications and guidance.
Rejudgment record. New verdict — Accepted the reduction in laboratory-confirmed household transmission in CENTERSTONE, but applied a C ceiling because symptomatic transmission was not significant and positive evidence is concentrated in a single Roche-led trial with a virologic endpoint
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced laboratory-confirmed influenza transmission to household contacts after one dose in the index patient | C | CENTERSTONE found a reduction from 13.4% to 9.5%, but the outcome was virologic and comes from one manufacturer-led trial. |
| Reduced symptomatic influenza transmission to household contacts | ? | The numerical difference of 5.8% versus 7.6% was not statistically significant, so efficacy is unconfirmed. |
| Shorter symptom-alleviation time for the infected patient | ? | CAPSTONE-1 was positive, but personal symptom treatment is a separate efficacy axis from household transmission and is not graded in this verdict. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Monto AS et al. CENTERSTONE. 2025 | Multicountry randomized double-blind placebo-controlled phase 3b trial | 2,681 | F. Hoffmann-La Roche and others; multiple company-affiliated authors | Laboratory-confirmed and symptomatic household transmission through day 5 | Laboratory-confirmed transmission fell to 9.5% versus 13.4%, but symptomatic transmission at 5.8% versus 7.6% was not significant. | Pivotal direct trial with a positive surrogate and nonsignificant clinical endpoint |
| Hayden FG et al. CAPSTONE-1. 2018 | Randomized double-blind placebo- and active-controlled phase 3 personal-treatment trial | 1,064 | Shionogi | Personal symptom-alleviation time, viral load, and resistance substitutions | Median symptom-alleviation time was 53.7 hours versus 80.2 hours with placebo, and reduced-susceptibility substitutions emerged in 9.7% in phase 3. | Context for single dosing and resistance; not direct transmission-prevention evidence |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Baloxavir marboxil x reduced household influenza transmission after one dose in the index patient — Evidence Grade C·52. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/baloxavir-single-dose-household-influenza-transmission/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.